


RealRate

MEDICINAL PRODUCTS 2017

MYRIAD GENETICS INC Rank 3 of 44









MEDICINAL PRODUCTS 2017



MYRIAD GENETICS INC Rank 3 of 44



The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 96% points. The greatest weakness of MYRIAD GENETICS INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 197% points above the market average of -47%.

Input Variable	Value in 1000 USD
Assets, Current	314,500
Assets, Non-Current	84,900
General and Administrative Expense	491,900
Goodwill	422,800
Liabilities, Current	72,300
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-2,500
Other Expenses	68,100
Other Liabilities	60,100
Other Net Income	2,100
Other Revenues	753,800
Property, Plant and Equipment, Net	58,300
Research and Development	70,600

Output Variable	Value in 1000 USD
Liabilities	132,400
Assets	880,500
Expenses	630,600
Revenues	753,800
Stockholders Equity	748,100
Net Income	125,300
Comprehensive Net Income	124,050
Economic Capital Ratio	150%

